Endo International(ENDP) announced that one of its operating companies, Par Pharmaceutical, has begun shipping the authorized generic version of Merck’s Noxafil 200 mg/5 mL oral suspension in the U.S.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Bayer motion to dismiss Merck complaint granted in fight over asset deal
- OncoSec announces results from Phase 2 KEYNOTE-695 clinical trial
- Gritstone initiated with an Outperform at Evercore ISI
- FDA grants full approval for Merck’s Keytruda in MSI-H or dMMR tumors
- Merck downgraded to Hold at Societe Generale on Keytruda patent cliff